|
Fair Value Measurements - Additional Information (Detail) (USD $)
|
3 Months Ended | 12 Months Ended | |||||||
|---|---|---|---|---|---|---|---|---|---|
|
Sep. 28, 2013
|
Sep. 29, 2012
|
Sep. 28, 2013
|
Sep. 29, 2012
|
Sep. 24, 2011
|
Sep. 28, 2013
Molecular Diagnostics [Member]
|
Sep. 29, 2012
Mammosite [Member]
|
Sep. 28, 2013
Credit Agreement [Member]
|
Aug. 01, 2012
Credit Agreement [Member]
|
|
| Fair Value Measurement [Line Items] | |||||||||
| Cash and cash equivalents, fair value | $ 300,000 | $ 300,000 | |||||||
| Impairment of goodwill | 1,100,000,000 | 5,800,000 | 1,117,369,000 | 5,826,000 | 1,100,000,000 | 5,800,000 | |||
| Cost-method equity investments in non-publicly traded securities | 12,600,000 | 16,000,000 | 12,600,000 | 16,000,000 | |||||
| Other-than-temporary impairment charge | 6,400,000 | 2,400,000 | |||||||
| Borrowed principal under credit agreement | 2,240,000,000 | 2,500,000,000 | |||||||
| Fair value of Senior Notes | $ 1,050,000,000 | $ 1,050,000,000 | |||||||